Faldaprevir - Trek Therapeutics
Alternative Names: BI-201335; BI-201335-NA; BI-201335-sodium; BI-201335Na; Faldaprevir-sodiumLatest Information Update: 11 Oct 2023
At a glance
- Originator Boehringer Ingelheim
- Developer Boehringer Ingelheim; Trek Therapeutics
- Class Amides; Antivirals; Carboxylic acids; Cyclopropanes; Oligopeptides; Pyrrolidines; Quinolines; Small molecules; Thiazoles
- Mechanism of Action Hepatitis C virus NS3 protein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Hepatitis C
Most Recent Events
- 11 Oct 2023 No development reported - Phase-II for Hepatitis C (Combination therapy, Treatment-naive) in New Zealand (PO) (Trek therapeutics pipeline, October 2023)
- 11 Oct 2023 No development reported - Phase-II for Hepatitis C (Combination therapy, Treatment-naive) in USA (PO) (Trek therapeutics pipeline, October 2023)
- 01 Sep 2017 Trek Therapeutics completes a phase II trial in Hepatitis C (Combination therapy, Treatment-naive) in New Zealand and USA (PO) (NCT02716428)